Global Cell Fractionation Market (Cell Lysis Market) Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product, Type Of Cell, End User & Region – Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 2538
Pages: 175

Global Cell Fractionation Market Size (2023 to 2028)

The size of the global cell fractionation market is estimated to be growing at a CAGR of 10.50% during the forecast period. The size of the market is predicted to be worth USD 6.44 billion by 2028 from USD 3.91 billion in 2023.

Cell fractionation, also known as cell lysis, is a process of separating cellular components while preserving the individual functions of each component. 

MARKET DRIVERS:

The growing prevalence of chronic diseases is one of the key factors propelling the growth of the cell fractionation market. The patient population of chronic diseases is on the rise and is predicted to grow significantly in the future. Researchers and healthcare professionals use the technique of cell fractionation with the tools to delve deeper into the cellular level and unravel the complexities of various diseases. Cell fractionation is also used to isolate specific cell types from patient samples for analysis and research purposes and helps in the development of personalized cancer treatment plans. The growing need to advance our understanding and develop innovative strategies for managing and treating chronic diseases is estimated to fuel the demand for cell fractionation and contribute to market growth.

The growing number of advancements in cell-based research and therapies such as regenerative medicine and cell-based immunotherapies further boost the growth rate of the cell fractionation market. Cell fractionation plays an important role in isolating the populations of certain cells such as stem cells or progenitor cells that can be further used in tissue engineering, regenerative therapies and cell-based therapies. The rapid shift towards personalized medicine, growing investments in research and development activities focused on cell fractionation technologies and ongoing advancements in cell fractionation technologies, such as microfluidics, high-throughput screening, and automation drive the cell fractionation market growth.

The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and vaccines, rising emphasis on stem cell research, favorable initiatives and funding from the governments for research and development activities in the field of cell fractionation and rising awareness and acceptance of cell-based therapies among healthcare professionals and patients boost the market’s growth rate. The growing pharmaceutical and biotechnology industries, an increasing focus on cell-based R&D, a growing number of applications of cell fractionation in diagnostic testing, such as liquid biopsy for cancer detection and characterization and the rising adoption of single-cell analysis contribute to the cell fractionation market growth.

Factors such as the growing number of collaboration activities between research institutions, biotechnology companies, and academic centers, the integration of cell fractionation technologies with other platforms, such as flow cytometry, mass spectrometry, and next-generation sequencing, rising need for organ transplantation requires efficient cell fractionation techniques for isolating specific cell types, such as stem cells or immune cells from donor organs fuel the growth rate of the cell fractionation market.

MARKET RESTRAINTS:

The high costs associated with cell-based research are one of the key factors hampering the cell fractionation market growth. Cell-based research providers or public servicers should spend high expenditures. The lack of skilled personnel further limits the growth rate of the cell fractionation market. Moreover, the survival of new entrants also leads to restraint in the cell fractionation market. The complexity, lack of standardization, sample variability and limited applications of cell fractionation further inhibit the market’s growth rate. The competition from alternative techniques that offer similar capabilities is another notable roadblock to cell fractionation market growth.

Impact of COVID-19 on the global cell fractionation market:

The cell fractionation market is affected by COVID-19 in many ways, especially economically. COVID-19 impacted the cell fractionation market in financial growth. Moreover, the supply chain of manufactured products is affected by the COVID-19 pandemic. Therefore, the cell fractionation market will regain the loss during the pandemic. Therefore, the cell fractionation market will be on track in the upcoming years.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2022 to 2028

Base Year

2022

Forecast Period

2023 to 2028

Segments Covered

By Product, Cell Type, End-User, Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

This research report has segmented and sub-segmented the global cell fractionation market based on the product, cell type, end-user, and region.

Cell Fractionation Market - By Product:

  • Consumables
  • Reagents
    • Enzymes
    • Detergent Solutions
  • Beads
  • Disposables
  • Instruments
    • Sonicator
    • Homogenizer

By product, the consumables segment held the largest share of the global cell fractionation market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The wide adoption of consumables in research and clinical settings, advancements in material technology and the development of specialized consumables for specific fractionation techniques drive the segmental growth.

The reagents segment is anticipated to account for a substantial share of the global market during the forecast period. The growing demand for specific and high-quality reagents for cell fractionation, advancements in molecular biology and biochemistry and rising focus on personalized medicine and biomarker discovery contribute to the segmental growth. On the other hand, enzymes are most frequently used for chemical cell disruption.

The sonicators segment is expected to grow at a healthy CAGR during the forecast period owing to the growing usage of cell lysis. However, the high cost of sonicators is limiting the growth rate of this segment.  

Cell Fractionation Market – By Cell Type:

  • Microbial
  • Mammalian

Based on cell type, the mammalian segment was the leader and accounted for a major share of the global market in 2022 and is expected to grow at a promising CAGR during the forecast period. Factors such as the growing investments by governmental and non-governmental organizations for cell-based research, the rising prevalence of diseases such as cancer and HIV/AIDS and increasing demand for advanced treatment options and the development of cell therapies.

The microbial segment is expected to hold a considerable share of the global market during the forecast period.

Cell Fractionation Market – By End User:

  • Research Laboratories
  • Biopharmaceutical
  • Biotechnology Companies

Based on the end-user, the research laboratories segment is predicted to account for the major share of the global cell fractionation market during the forecast period. The continuous demand for advancements in basic research to uncover fundamental cellular mechanisms and processes drives the need for advanced techniques like cell fractionation and drives segmental growth. The rising emphasis on personalized medicine and targeted therapies and technological advancements in cell fractionation techniques, such as improved centrifugation methods, microfluidics, and high-throughput automation further propel the segmental growth.

Cell Fractionation Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Geographically, North America held the major share of the global market in 2022. The domination of the North American region in the global market is likely to continue throughout the forecast period. The presence of well-established healthcare infrastructure, including research institutions, academic centers, and biotechnology hubs and technological advancements in the life sciences sector primarily drive the cell fractionation market in North America. The presence of several leading biopharmaceutical companies engaged in drug development and manufacturing and the increasing number of government initiatives and funding programs that promote scientific research and innovation further fuel the growth rate of the North American market. The growing number of collaborations and partnerships between academic institutions, research organizations, and industry players and increasing R&D efforts in genomics and proteomics favor cell fractionation market growth in the North American region. The U.S. dominated the market in North America in 2022, followed by Canada.

Europe is the second biggest regional market for cell fractionation in 2022 and is predicted to hold a notable share of the global market during the forecast period. The presence of a robust biotechnology sector with numerous biotech companies and research organizations, substantial support and funding for research and development in the life sciences sector from European countries and increasing focus on precision medicine and personalized therapies drive the European cell fractionation market growth. The growing number of collaborations among research institutions and industry players through networks and partnerships, an increasing number of advancements in bioprocessing technologies to improve the efficiency and scalability of cell fractionation processes and a strong presence in stem cell research and regenerative medicine in Europe further boost the growth rate of the European market. The UK, Germany and France are expected to account for the leading share of the European market during the forecast period.

APAC is anticipated to hit the highest CAGR among all the regions in the worldwide market during the forecast period. The growing number of investments in the life sciences sector from APAC countries such as China, Japan, and South Korea, substantial growth in the biopharmaceutical industry, increase in healthcare expenditure and the growing number of initiatives and policies to promote research and development in the life sciences majorly drive the APAC cell fractionation market growth. The growing adoption of cell fractionation in precision agriculture practices for crop improvement and sustainable farming further promotes regional market growth. China followed by Japan and India is predicted to hold the major share of the APAC market during the forecast period.

The Latin American cell fractionation market is predicted to account for a considerable share of the global market during the forecast period owing to factors such as the growing biotechnology sector and an increasing number of investments to improve healthcare infrastructure and research capabilities. Brazil led the market in Latin America, followed by Mexico in 2022.

The MEA cell fractionation market is estimated to register a steady CAGR during the forecast period. The growing biomedical research and drug discovery activities, rising awareness of personalized medicine, an increasing number of initiatives to promote life sciences research and development and the rising prevalence of infectious diseases drive the MEA market growth.

KEY MARKET PLAYERS:

Some of the prominent companies leading the global cell fractionation market profiled in this report are Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffman-La Roche AG, Merck KGaA, Miltenyi Biotec, QIAGEN N., Qsonica and Thermo Fisher Scientific Inc.

RECENT MARKET HAPPENINGS:

  • In 2020, Thermo Fisher Scientific teamed up with Northeastern University to promote research in precision medicine, monoclonal antibodies, and gene and cell therapies around the biopharmaceutical industry.
  • In 2020, Danaher Corporation purchased the biopharma division from GE Company's life science unit. Danaher is a leading research and technology innovator to assist consumers in overcoming challenging problems and strengthening the global quality of living. Its world-class brands hold leading positions in the competitive and appealing healthcare, environmental, and applied end-markets.
  • In March 2020, the Canadian Government spent approximately USD 7.0 million on stem cell science in Canada under the Stem CNetwork'srk's competitive research funding scheme.
  • In 2019, the Canadian Minister of Science and Sport reported USD 22.7 million in funding from Genome Canada and USD 33.4 million from provincial governments to support 36 research projects. The programs cover various topics, including medicine, nutrition, natural resources, and the atmosphere.

Please wait. . . . Your request is being processed

Frequently Asked Questions

How much was the global cell fractionation market worth in 2021?

The global cell fractionation market size was worth USD 3.2 billion in 2021.

What is the CAGR of the cell lysis market?

The global cell lysis market is expected to grow at a CAGR of 10.5% from 2022 to 2027.

Which region led the cell fractionation market in 2021?

The North American region was the largest region in the global cell fractionation market in 2021.

Which are the companies playing a key role in the global cell fractionation market?

Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffman-La Roche AG, Merck KGaA, Miltenyi Biotec, QIAGEN N., Qsonica and Thermo Fisher Scientific Inc. are a few of the promising players in the cell fractionation market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample